Why the Parsortix Platform?
Marker-Independent CTC Enrichment
Captures individual CTCs and CTC clusters of varying sizes, independent of surface marker expression.
Intact, Viable Cell Recovery
Recover cells suitable for multiomic analysis – DNA, RNA, protein, imaging, and functional studies.
Broad Phenotypic Coverage
Enables isolation of epithelial, mesenchymal, and EMT phenotypes, including more invasive and treatment-resistant populations.
Seamless Laboratory Integration
Semi-automated workflow with no pre-processing required: designed to integrate into existing lab environments.
With published research across 19 cancer types representing more than 65% of solid tumors, Parsortix is the most widely published marker-independent CTC enrichment platform globally.
Workflow
Blood Collection
Collection of blood sample into vacutainer.
Automated Blood Processing
Prime the cassette. Insert your sample and press start – no preprocessing required. Blood is pumped through the cassette with minimal user input.
Cell Capture
Proprietary single use cassette captures CTCs in the critical gap.
Cell Imaging or Recovery
Examine cells in the cassette or reverse the flow to recover cells in buffer for multiple downstream analysis techniques.
Cells Recovered From the Parsortix Platform are Suitable for Multiomic Analysis and are Compatible with Numerous Downstream Analysis Techniques
Genomic
Genomic
Parsortix-enriched CTCs are suitable for both targeted and whole genome analyses, including NGS and PCR.
Transcriptomic
Transcriptomic
As intact cells, Parsortix-enriched CTCs are suitable for molecular applications including RNA sequencing.
Proteomic
Proteomic
Downstream applications such as IHC and IF imaging enable the assessment of specific nucleic acid targets and protein expression.
Functional
Functional
As viable cells, Parsortix-enriched CTCs can be cultured and used for preclinical studies e.g. xenografts.
Efficient Performance with Widespread Adoption
Efficient cell capture and release for multiple cell lines
Efficient cell capture and release for multiple cell lines
The Parsortix Platform has been tested in multiple cancer cell lines, and in over 120 independent research publications investigating 19 cancer types representing >65% of all solid tumours.
Isolate and harvest CTC clusters with high metastatic potential
Isolate and harvest CTC clusters with high metastatic potential
Recover CTC clusters regardless of phenotype - including mesenchymal cells and those undergoing EMT. With their high metastatic potential, CTC clusters provide insight into cancer progression and treatment response.
Independent Expert Consensus Highlights the Parsortix Platform as a Next-Generation CTC Technology for Future Clinical Applications1
Read the articleParsortix Platform
Take a Closer Look at CTC Harvesting in Action
References
1. Nicolò, E. et al. International expert consensus on the clinical integration of circulating tumor cells in solid tumors. European Journal of Cancer, 231, 116050. (2025).
2. Davies, C. R. et al. The potential of using circulating tumour cells and their gene expression to predictdocetaxel response in metastatic prostate cancer. Front. Oncol. 12, 1060864 (2023).
3. Obermayr, E. et al. Gene expression markers in peripheral blood and outcome in patients with platinum resistant ovarian cancer: A study of the European GANNET53 consortium. Int. J. Cancer ijc.34978 (2024).
4. Ring, A. et al. Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer. Ann. Surg. Oncol. 29, 2882–2894 (2022).
5. Bayou, N. et al. Quantitative HER2 profiling on circulating tumor cells using an EpCAM-independent platform in metastatic breast cancer. Cancer Cell Int. 25, 439 (2025).
6. Markou, A. N. et al. Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung Cancer. Cancers 15, 1877 (2023).
7. Kurzeder, C. et al. Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial. Nat. Med. 31, 1120–1124 (2025).
8. Bowley, T. Y. et al A Melanoma Brain Metastasis CTC Signature and CTC:B-cell Clusters Associate with Secondary Liver Metastasis: A Melanoma Brain-Liver Metastasis Axis. Cancer Research Communications, 5(2), 295–308 (2025).